The conversation is about whether the phase 2 results for pyrilutamide, a potential hairloss treatment, were presented at a dermatology convention and inquiries about the completion of phase 3 trials. Specific treatments mentioned include pyrilutamide.
The post is a humorous take on the author's experience with hairloss and using finasteride for six months. The conversation includes discussions about hairloss, treatments like finasteride, and personal experiences with baldness.
Hairloss treatments, including microneedling, minoxidil, finasteride and RU58841; the efficacy of these treatments; criticisms of Kevin Mann's content related to his selective data presentation and biases towards certain treatments; and other topics such as DHT being labeled a "trash hormone" and critiques of other hairloss YouTubers.
A user shared their hairloss transformation using Minoxidil, Finasteride, and DermaStamp, showing significant improvement over time. They noted quitting DermaStamp due to laziness and attributed past poor results to heavy smoking.
The user is discussing their hairloss treatment progress, using topical Minoxidil, oral Finasteride, derma stamping, and Ketoconazole shampoo. Some replies express skepticism about the results, while others show support or comment on the presentation of the progress pictures.
This conversation discusses the advancements in treatments for hairloss, including finasteride, dutasteride, minoxidil and new promising treatments such as pyrilutamide and verteporfin. Other treatments discussed were taking minoxidil orally, tretinoin to turn non-responders into responders and microneedling to further boost growth.
An 18-year-old male switched from topical finasteride and minoxidil to oral dutasteride for diffuse hairloss and saw improvement without side effects, despite experiencing scalp itch and shedding. Commenters noted significant hair regrowth and were surprised by his young age and appearance.
Minoxidil can regrow hair but doesn't address the underlying issue of DHT, leading to continued hairloss. Users discuss their experiences with finasteride and dutasteride, mentioning side effects, personal outcomes, and alternatives like microdosing topical finasteride.
The conversation discusses why the difference between donor and balding hair isn't studied more to find a cure for hairloss. Treatments mentioned include Minoxidil, finasteride, and RU58841.
Hairloss treatments, specifically the use of finasteride, microneedling and potentially oral minoxidil. People discussed their experiences with finasteride, its effects on sexual behaviors, as well as potential solutions such as tadalafil or using other growth factor signal peptides for hope in curing male pattern baldness.
Hairloss treatments discussed include Minoxidil, Finasteride, and RU58841. Pyrilutamide Phase 2 results are expected in June 2022, with hopes for a better alternative to current treatments.
Hopeful treatments for hairloss, including Verteporfin, Androgen Receptor Degradation, and SCUBE3. These treatments offer potential solutions to slow or stop the effects of androgens on the scalp.
Shiseido's hairloss treatment reported only 5% regrowth, disappointing many. Users discussed other treatments like Minoxidil, finasteride, RU58841, and CB-03-01 as potential alternatives.
A user's progress with a hairloss treatment regimen consisting of minoxidil, finasteride, and dermarolling once a week over four months; other users have offered encouragement and advice.
Kintor's Pyrilutamide results for hairloss treatment will be released soon. The treatment may replace current treatments like finasteride and minoxidil without systemic side effects.
People are discussing using tretinoin with minoxidil for hairloss treatment, focusing on application methods and results. Microneedling is mentioned as a separate method to promote hair growth, with some debate on its effectiveness in enhancing minoxidil absorption.
How diffuse unpatterned alopecia (DUPA) is not an invitation to self-diagnose oneself with aggressive AGA and that seeking a specialized dermatologist may help people experiencing hairloss. Treatment options discussed include topical clobetasol propionate, oral minoxidil, and discontinuing finasteride.
The conversation discusses whether to use finasteride for hairloss, considering its role in inhibiting DHT and 5AR, which can affect brain function and mood. Some users report anxiety and depression from finasteride, while others do not experience these side effects and emphasize the importance of DHT for brain and prostate health.
A user is considering using RU58841 to treat hairloss and asks if it can be effective for 4-5 years. Some suggest starting with a lower concentration and debate the safety of RU58841 compared to approved drugs like finasteride.
Breezula® (Clascoterone) showed promising results in a Phase 2 trial for treating hairloss, being as effective as Propecia with no serious side effects. It might be released between 2021-2022, and a related acne treatment with the same active ingredient could be used in the meantime.
Follicopeptide (FOL005) by Coegin Pharma will launch as a cosmetic hair growth treatment by Q2 2025, showing similar efficacy to finasteride. Users discuss the benefits and skepticism of releasing hairloss treatments as cosmetics rather than drugs.
User shared 15-month progress using Oral Dutasteride and Sublingual Minoxidil for hairloss. Treatment improved hair density, now considering hair transplant with fewer grafts.
Pyrilutamide, a new drug being tested to combat hairloss that has been found to perform comparably or better than finasteride and dutasteride in the initial 6 months of treatment with minimal reported side effects.
Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hairloss treatments.
SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hairloss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.
The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hairloss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.
Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hairloss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.